GH Research PLC (GHRS)
GHRS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | GHRS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Ireland |
| IPO year | 2021 |
| SEC CIK | 0001855129 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Ireland |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-05 |
| Cash and burn | $246.3M cash; operating cash flow -$10.9M a quarter. | Report 2025-12-31 |
| Shares outstanding | 62,029,395 (2025-12-31); 52,028,145 a year earlier; 52,020,849 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-05-14 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers, Dublin, Ireland | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$48.3M | -$43.6M | $246.3M | $0 | Needs four quarters | 20-F 2026-03-05 |
| FY 2024 2024-12-31 | Not filed | -$39.0M | -$42.3M | $100.8M | $0 | Needs four quarters | 20-F 2026-03-05 |
| FY 2023 2023-12-31 | Not filed | -$35.6M | -$33.3M | $78.4M | $0 | Needs four quarters | 20-F 2026-03-05 |
| FY 2022 2022-12-31 | Not filed | -$22.5M | -$26.2M | $166.0M | $0 | Needs four quarters | 20-F/A 2025-07-29 |
| FY 2021 2021-12-31 | Not filed | -$9.2M | -$15.3M | $276.8M | $0 | Needs four quarters | 20-F 2024-03-07 |
| FY 2020 2020-12-31 | Not filed | -$446K | -$330K | $5.9M | No debt tags | Needs four quarters | 20-F/A 2023-06-02 |
| FY 2019 2019-12-31 | Not filed | -$310K | -$289K | $498K | No debt tags | Needs four quarters | 20-F 2022-03-28 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2026-05-14 |
| Latest annual report | 20-F | 2026-03-05 |
| Latest quarterly / interim | 6-K | 2026-11-13 |
Source: SEC EDGAR submissions feed, 203 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.6% |
| 1 month | +1.3% |
| 3 months | -32.2% |
| Year to date | +50.4% |
| 1 year | +39.2% |
| From 52-week high | -37.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MLYS | Mineralys Therapeutics Inc. | $14.53 | -5.22% | $1.3B |
| MNKD | MannKind Corporation | $3.96 | -4.24% | $1.3B |
| INVA | Innoviva Inc. | $18.49 | -2.84% | $1.3B |
| OCUL | Ocular Therapeutix Inc. | $6.01 | -3.22% | $1.3B |
| AVLN | Avalyn Pharma Inc. | $29.76 | -1.72% | $1.3B |
| NKTR | Nektar Therapeutics | $36.44 | -2.23% | $1.2B |
| AMPH | Amphastar Pharmaceuticals Inc. | $29.17 | -0.68% | $1.2B |
| GPCR | Structure Therapeutics Inc. | $18.57 | -7.15% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier